— Know what they know.
Not Investment Advice
Also trades as: INFI (NASDAQ) · $vol 0M

INFIQ OTC

Infinity Pharmaceuticals, Inc.
1W: -99.0% 1M: -99.0% 3M: +0.0% YTD: -99.0% 1Y: -98.0% 3Y: -100.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
Weekly Expected Move ±9113.7%
$-0 $-0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 51 · $9076 mcap · 90M float · 0.0075% daily turnover · Short 18% of daily vol

Balance Sheet Trends

Total Assets
$42M -50.3% ▼
3Y CAGR: -4.9%
Total Liabilities
$61M -3.2% ▼
3Y CAGR: +14.0%
Shareholders Equity
-$19M -188.3% ▼
Cash & Investments
$38M -52.5% ▼
3Y CAGR: -3.4%
Total Debt
$48M -5.7% ▼
3Y CAGR: +14.7%
Net Debt
$10M +112.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022
— Assets —
Cash$22M$29M$81M$38M
Short-Term Investments$20M$6M$0$0
Cash & ST Investments$42M$34M$81M$38M
Net Receivables$0$0$0$0
Inventory$0$0$0$0
Other Current Assets$457K$384K$399K$560K
Total Current Assets$45M$36M$82M$40M
Property, Plant & Equip.$4M$3M$2M$1M
Goodwill & Intangibles$0$0$0$0
Long-Term Investments$315K$165K$158K$158K
Other Non-Current Assets$215K$5K$54K$194K
Total Non-Current Assets$4M$3M$3M$2M
Total Assets$49M$39M$85M$42M
— Liabilities —
Accounts Payable$2M$3M$2M$4M
Short-Term Debt$0$848K$897K$0
Deferred Revenue$7M$6M$9M$0
Other Current Liabilities-$2M-$2M-$2M$2M
Total Current Liabilities$10M$11M$13M$14M
Long-Term Debt$30M$22M$49M$47M
Other Non-Current Liab.$38K$28M$270K$37K
Total Non-Current Liabilities$32M$51M$50M$48M
Total Liabilities$41M$62M$63M$61M
— Equity —
Common Stock$57K$64K$89K$89K
Retained Earnings-$726M-$766M-$812M-$856M
Accumulated OCI$12K-$1K$0$0
Total Stockholders Equity$8M-$23M$22M-$19M
Total Liabilities & Equity$49M$39M$85M$42M
— Key Metrics —
Total Debt$32M$24M$51M$48M
Net Debt$10M-$4M-$79M$10M
Total Investments$20M$6M$158K$158K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms